| Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study J Cuzick, GP Swanson, G Fisher, AR Brothman, DM Berney, JE Reid, ... The lancet oncology 12 (3), 245-255, 2011 | 848 | 2011 |
| Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer G Attard, J Clark, L Ambroisine, G Fisher, G Kovacs, P Flohr, D Berney, ... Oncogene 27 (3), 253-263, 2008 | 572 | 2008 |
| Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort J Cuzick, DM Berney, G Fisher, D Mesher, H Møller, JE Reid, M Perry, ... British journal of cancer 106 (6), 1095-1099, 2012 | 439 | 2012 |
| Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer AHM Reid, G Attard, L Ambroisine, G Fisher, G Kovacs, D Brewer, J Clark, ... British journal of cancer 102 (4), 678-684, 2010 | 324 | 2010 |
| Complex patterns of ETS gene alteration arise during cancer development in the human prostate J Clark, G Attard, S Jhavar, P Flohr, A Reid, J De-Bono, R Eeles, ... Oncogene 27 (14), 1993-2003, 2008 | 204 | 2008 |
| Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort J Cuzick, S Stone, G Fisher, ZH Yang, BV North, DM Berney, L Beltran, ... British journal of cancer 113 (3), 382-389, 2015 | 169 | 2015 |
| Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study DM Berney, A Gopalan, S Kudahetti, G Fisher, L Ambroisine, CS Foster, ... British journal of cancer 100 (6), 888-893, 2009 | 167 | 2009 |
| Long-term outcome among men with conservatively treated localised prostate cancer J Cuzick, G Fisher, MW Kattan, D Berney, T Oliver, CS Foster, H Møller, ... British journal of cancer 95 (9), 1186-1194, 2006 | 167 | 2006 |
| SOX9 Elevation in the Prostate Promotes Proliferation and Cooperates with PTEN Loss to Drive Tumor Formation MK Thomsen, L Ambroisine, S Wynn, KSE Cheah, CS Foster, G Fisher, ... Cancer research 70 (3), 979-987, 2010 | 166 | 2010 |
| Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort G Fisher, ZH Yang, S Kudahetti, H Møller, P Scardino, J Cuzick, ... British journal of cancer 108 (2), 271-277, 2013 | 158 | 2013 |
| Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome DM Berney, L Beltran, G Fisher, BV North, D Greenberg, H Møller, ... British journal of cancer 114 (10), 1078-1083, 2016 | 154 | 2016 |
| Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer G Attard, J Clark, L Ambroisine, IG Mills, G Fisher, P Flohr, A Reid, ... British journal of cancer 99 (2), 314-320, 2008 | 131 | 2008 |
| Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer J Cuzick, ZH Yang, G Fisher, E Tikishvili, S Stone, JS Lanchbury, ... British journal of cancer 108 (12), 2582-2589, 2013 | 127 | 2013 |
| Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers RA Yates, M Dowsett, GV Fisher, A Selen, PJ Wyld British journal of cancer 73 (4), 543-548, 1996 | 114 | 1996 |
| Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement CS Foster, AR Dodson, L Ambroisine, G Fisher, H Møller, J Clark, G Attard, ... British journal of cancer 101 (7), 1137-1144, 2009 | 98 | 2009 |
| Nomogram incorporating PSA level to predict cancer‐specific survival for men with clinically localized prostate cancer managed without curative intent MW Kattan, J Cuzick, G Fisher, DM Berney, T Oliver, CS Foster, H Møller, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 81 | 2008 |
| p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer S Kudahetti, G Fisher, L Ambroisine, C Foster, V Reuter, J Eastham, ... BJU international 104 (1), 20-24, 2009 | 67 | 2009 |
| PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention S Yao, A Bee, D Brewer, A Dodson, C Beesley, Y Ke, L Ambroisine, ... Genes & cancer 1 (5), 444-464, 2010 | 58 | 2010 |
| Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading DM Berney, G Fisher, MW Kattan, RTD Oliver, H Møller, P Fearn, ... BJU international 100 (6), 1240-1244, 2007 | 53 | 2007 |
| Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind‐up of the second pain response in healthy male volunteers AM Hughes, J Rhodes, G Fisher, M Sellers, JW Growcott British journal of clinical pharmacology 53 (6), 604-612, 2002 | 51 | 2002 |
